Abstract
Results of Single-Arm, Phase 1b Study of Anti-C1q Treatment (ANX009) Show that the Classical Pathway Is a Key Driver of Complement Activation and Consumption in Patients with Active Lupus Nephritis
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
